 BAUDETTE, Minn.--BUSINESS WIRE--ANI Pharmaceuticals, Inc. ANI or the Company Nasdaq: ANIP today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administrations FDA approval of the Companys prior approval supplement application PAS. The current annual U.S. market for Prazosin 1mg and 2mg strengths is approximately 46.2 million, according to IQVIAIMS Health. Launch of Prazosin HCl is ANIs fourteenth re-commercialization of a 